CLINICAL TRIALS PROFILE FOR MYCAPSSA
✉ Email this page to a colleague
All Clinical Trials for MYCAPSSA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01412424 ↗ | Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly | Completed | Chiasma, Inc. | Phase 3 | 2012-03-01 | MYCAPSSA™ (formerly Octreolin™) is a proprietary oral form of the approved injectable medical product octreotide used to treat acromegaly. This study will evaluate the efficacy and safety of MYCAPSSA™ treatment in patients with acromegaly. |
| NCT03252353 ↗ | Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly | Active, not recruiting | Chiasma, Inc. | Phase 3 | 2017-09-01 | Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated maintenance of biochemical response up to 13 months in the majority of patients with acromegaly previously managed with somatostatin analog injections (reference below). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MYCAPSSA
Condition Name
Clinical Trial Locations for MYCAPSSA
Trials by Country
Clinical Trial Progress for MYCAPSSA
Clinical Trial Phase
Clinical Trial Sponsors for MYCAPSSA
Sponsor Name
